Noubar Afeyan Sells 10,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Posted by MarketBeat News on Mar 5th, 2023

Moderna, Inc. (NASDAQ:MRNA – Get Rating) Director Noubar Afeyan sold 10,000 shares of Moderna stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $139.00, for a total transaction of $1,390,000.00. Following the transaction, the director now directly owns 2,187,209 shares of the company’s stock, valued at $304,022,051. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Noubar Afeyan also recently made the following trade(s):

On Wednesday, February 22nd, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $160.35, for a total transaction of $1,603,500.00.
On Wednesday, February 15th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $173.17, for a total transaction of $1,731,700.00.
On Wednesday, February 8th, Noubar Afeyan sold 20,000 shares of Moderna stock. The stock was sold at an average price of $167.84, for a total transaction of $3,356,800.00.
On Wednesday, January 25th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $194.33, for a total transaction of $1,943,300.00.
On Wednesday, January 18th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $200.20, for a total transaction of $2,002,000.00.
On Wednesday, January 11th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $188.57, for a total transaction of $1,885,700.00.
On Wednesday, January 4th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $182.15, for a total transaction of $1,821,500.00.
On Wednesday, December 21st, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $201.70, for a total transaction of $2,017,000.00.
On Wednesday, December 14th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $195.00, for a total transaction of $1,950,000.00.
On Wednesday, December 7th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $172.16, for a total transaction of $1,721,600.00.

Moderna Stock Up 3.9 %

Moderna stock opened at $143.20 on Friday. The stock has a market capitalization of $55.32 billion, a PE ratio of 7.17 and a beta of 1.70. Moderna, Inc. has a twelve month low of $115.03 and a twelve month high of $217.25. The company has a quick ratio of 2.54, a current ratio of 2.73 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average of $174.54 and a 200-day moving average of $160.40.

Want More Great Investing Ideas?

Moderna (NASDAQ:MRNA – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The company reported $3.61 earnings per share for the quarter, missing the consensus estimate of $4.66 by ($1.05). The company had revenue of $5.08 billion during the quarter, compared to analyst estimates of $5.02 billion. Moderna had a net margin of 43.41% and a return on equity of 46.34%. The firm’s quarterly revenue was down 29.5% compared to the same quarter last year. During the same quarter last year, the company earned $11.29 EPS. On average, equities research analysts anticipate that Moderna, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MRNA. JPMorgan Chase & Co. lifted their price target on shares of Moderna from $132.00 to $138.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 8th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Moderna from $225.00 to $200.00 and set a “buy” rating for the company in a research report on Tuesday, February 28th. Bank of America lifted their price target on shares of Moderna from $160.00 to $182.00 in a research report on Tuesday, November 15th. SVB Leerink cut shares of Moderna from a “market perform” rating to an “underperform” rating and decreased their price objective for the company from $111.00 to $93.00 in a report on Friday, February 24th. Finally, Chardan Capital boosted their price objective on shares of Moderna from $191.00 to $208.00 and gave the company a “neutral” rating in a report on Wednesday, January 18th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $180.86.

Institutional Trading of Moderna

Institutional investors have recently made changes to their positions in the business. Ronald Blue Trust Inc. lifted its position in shares of Moderna by 307.4% in the fourth quarter. Ronald Blue Trust Inc. now owns 220 shares of the company’s stock worth $26,000 after purchasing an additional 166 shares in the last quarter. Roble Belko & Company Inc bought a new stake in shares of Moderna in the fourth quarter worth $27,000. ICA Group Wealth Management LLC bought a new stake in shares of Moderna in the fourth quarter worth $27,000. Evoke Wealth LLC lifted its position in shares of Moderna by 100.8% in the third quarter. Evoke Wealth LLC now owns 239 shares of the company’s stock worth $28,000 after purchasing an additional 120 shares in the last quarter. Finally, Guardian Wealth Advisors LLC bought a new stake in shares of Moderna in the third quarter worth $28,000. Institutional investors own 63.11% of the company’s stock.

Moderna Company Profile

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.